Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAPI PET vs FDG PET for Diagnosis and Follow-up of Giant Cell Arteritis
2025-523880-39-02Phase 3Authorised
- Sponsor
- UZ Leuven
- Start
- Feb 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of [18F]AlF-FAPI-74 in giant cell arteritis (GCA) (2 arms), sponsored by UZ Leuven. Planned start Feb 2026; status: authorised.
02
Drugs
[18F]AlF-FAPI-74
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on 2025-523880-39-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523880-39-02.